Oral Answers to Questions

Clive Jones Excerpts

Tuesday 25th November 2025 Commons Chamber

[Dr Neil Hudson (Epping Forest) (Con)]

7. What assessment he has made of the potential impact of the time taken to deliver the new hospital programme on maintenance costs across the NHS estate.

[Clive Jones (Wokingham) (LD)]

22. What progress his Department has made on the implementation of the new hospital programme.

[The Minister for Secondary Care (Karin Smyth)]

In January we published an honest, realistic and deliverable plan that puts the programme on a sustainable footing, ensuring that taxpayers get the maximum value for money. We are committed to delivering all the schemes and are moving at pace, with funding in place for design work, construction and business case development. Outside the new hospital programme, we are investing £30 billion in day-to-day maintenance repairs of the NHS estate across this spending review period.

--- Later in debate ---

[Karin Smyth]

I think that the Conservatives’ constituents know exactly what their promises were built on: sand. That is why there are very few Conservative Members in the House and a lot of Members on the Labour Benches. We took hold of the programme and put it on a sustainable and credible footing, and we will deliver it.

[Clive Jones]

Frimley Park hospital is in wave 1 of the new hospital programme, with construction expected to start in 2028-29. Many of my constituents use the hospital, and they are rightly concerned about possible delays to its build, especially with the issue of reinforced autoclaved aerated concrete. Patients and staff cannot be expected to work in an unsafe environment longer than necessary, if at all. Will the Minister reassure my constituents and confirm that the construction on Frimley Park hospital will begin no later than 2029?

[Karin Smyth]

The hon. Gentleman is an assiduous campaigner on behalf of Royal Berkshire hospital and now of Frimley Park hospital. I met with Members of Parliament last week who are involved in the RAAC schemes, which are progressing to plan. We are absolutely on target with progressing that plan, and we look forward to the proposals coming through from the local integrated care board.

International Men’s Day

Clive Jones Excerpts

Thursday 20th November 2025 Commons Chamber

[Clive Jones (Wokingham) (LD)]

As we mark International Men’s Day, we have an opportunity to address the biggest inequality in men’s health: prostate cancer is the most common cancer in men, yet it is the only major cancer without a screening programme. Hopefully, the Secretary of State will ensure that that changes in the national cancer plan. We are approaching a pivotal moment on the path towards the UK’s first prostate cancer screening programme. We cannot afford to wait while more men miss out on lifesaving early diagnosis.

Some men face greater inequalities than others. Prostate Cancer UK reports that black men face twice the risk of prostate cancer, and men in deprived communities are 29% more likely to be diagnosed with late-stage, incurable prostate cancer. Without targeted and urgent action, those inequalities will only deepen. A national screening programme is urgently needed. It would result in earlier diagnosis, and we all know that when prostate cancer is identified early, survival outcomes are dramatically improved.

As I said, I am sure that the Secretary of State will ensure that prostate cancer will be a priority in the upcoming national cancer plan, but could he confirm that? Can he also confirm that GP guidelines will be updated so that they can start lifesaving conversations with men at risk? There must also be clear advice on a simple online risk checker, and the Government need to fund nationwide awareness programmes so that every man knows his risk and can act early.

Implementation of those four things would dramatically improve outcomes for many with prostate cancer. I am afraid there will be no dad jokes from me. My daughters constantly tell me that all my jokes are dad jokes, and that they are bad ones.

Obesity and Fatty Liver Disease

Clive Jones Excerpts

Tuesday 28th October 2025 Westminster Hall

[Dr Cooper]

I thank the hon. Member for making that excellent point. He is absolutely right. The issues of the NHS waiting lists are pertinent and stark. Reducing them will mean that we have to get the left shift right as well as invest in acute services.

Our policies have failed the population for decades. This debate is an opportunity to make the urgent case for a national liver strategy, joined-up public health work and profound reform of the conditions that stop us all living well. Because we have failed to build an environment where healthy food is affordable and accessible, two thirds of UK adults are now overweight or obese, and one in three children in England are above a healthy weight when they leave primary school.

Fatty liver disease is a silent killer, often asymptomatic until at a very advanced stage, meaning many patients are diagnosed too late for effective intervention. Left untreated, as too many are, fatty liver disease can progress to liver inflammation, fibrosis, cirrhosis, liver failure or liver cancer. Fatty liver disease also increases significantly the risk of heart attacks, stroke and heart failure. It is projected to overtake alcohol as the leading cause of liver transplants within a decade.

How do we treat fatty liver disease? Despite high and rising mortality rates, there are limited treatment options for patients with this disease. As I have said, weight loss and lifestyle change are essential.

[Clive Jones (Wokingham) (LD)]

I thank the hon. Member for bringing this very important subject to Westminster Hall. She is absolutely right. Fatty liver disease is the fastest rising cause of liver cancer death in the UK and highlights the risk of developing a less survivable cancer for people living with obesity. Does the hon. Member agree that improvements to diagnosis of and treatment for fatty liver disease should be covered in the national cancer plan, which I called for a year ago and the Government are to announce early next year?

[Dr Cooper]

I thank the hon. Member for his excellent intervention. I absolutely agree that the national cancer strategy is essential. We must make sure that liver cancer is integrated into it, and that diagnosis and treatment are a key part of it and are funded across the country, to make sure that the inequalities that I am going to talk about are addressed sufficiently.

Before we get to the issue of diagnosis and treatment, weight loss and lifestyle change are essential. We know that a Mediterranean diet plus exercise improves liver function and that reducing ultra-processed foods reduces intrahepatic fat. However, for those whose disease has progressed to scarring of the liver, or liver fibrosis, there is an urgent need for therapies that directly target the liver.

Currently, no drugs are licensed to treat fatty liver disease in the UK. We have fallen behind the United States and Europe, as our market is too small for prioritisation. If I might get a bit more political, that is driven in part by our decision to leave the European single market. But this is a rapidly advancing field and we are approaching a potential breakthrough in treatment. With adequate planning, co-ordinated action, investment and leadership, we can ensure that our national health system is patient-ready to deliver the next generation of medications, and that all patients, regardless of postcode, can benefit.

Early diagnosis offers significantly better outcomes and a wider range of treatment options, but despite fatty liver disease being medically recognised in the 1980s, clinical and public awareness of it remains far too low. We urgently need to increase public understanding and encourage early liver checks, particularly for those at higher risk because of obesity or type 2 diabetes. What is more, we have seen primary care systemic failures to improve early detection, such that three quarters of people are diagnosed with cirrhosis at hospital in an emergency, when it is too late for effective treatment or intervention.

NHS Workforce Levels: Impact on Cancer Patients

Clive Jones Excerpts

Thursday 23rd October 2025 Westminster Hall

[Clive Jones (Wokingham) (LD)]

I beg to move,

That this House has considered the impact of NHS workforce levels on cancer patients.

It is a pleasure to serve under your chairship, Ms Hobhouse. I declare an interest as a governor of the Royal Berkshire hospital. Also, a family member has shares in a medical company.

Being a cancer survivor, cancer diagnosis, treatment and outcomes are important to me. I thank the 136 people who responded to my survey ahead of this debate, and the Chamber engagement team for helping to highlight the real experiences of cancer patients across the country. I also thank all the organisations that have helped me and my office to prepare for the debate.

Shortfalls in the NHS workforce are no secret. Consultants, nurses, radiologists and oncologists are all working flat out to deliver care but are being held back by staff shortages, limited equipment, outdated buildings and a lack of training. This is a legacy of the last Conservative Government. The new Labour Government must act swiftly to support our NHS workforce and deliver world-class cancer care.

I welcome the commitment to a new national cancer plan that was confirmed on 4 February 2025—World Cancer Day—after I called for a national cancer plan on 31 October last year. That plan must prioritise early diagnosis and improved treatment. Perhaps it could even be launched on World Cancer Day 2026, which is 4 February.

According to Lilly UK, only one third of NHS staff believe there are enough people for them to perform their roles effectively. The Royal College of Radiologists reports a 29% shortfall in radiologists, or 1,670 consultants, which is set to rise to 39%, or 3,112 consultants, in five years. An extra 346 radiologists are now needed to clear the diagnostic backlog—equivalent to 9% of the current workforce. The Royal College of Pathologists found that 60% of consultants said their departments lack adequate resources, including staff.

Clinical oncology faces a 15% shortfall, forecast to reach 19% by 2029, with smaller cancer centres suffering vacancy rates six times higher than larger ones. In genomics, only 60% of tests are delivered on time, mainly due to a shortage of pathologists. In 2022, NHS England reported a 12% mammographer vacancy rate, rising to 15% in the midlands and south-east, and 36% of the workforce are due to retire within the next 10 to 15 years. Mike Richards’ 2020 review found that histopathology activity had increased by 30% between 2018 and 2019, while consultant numbers rose by just 8%. The gap continues to widen.

The UK also has among the lowest numbers of MRI, CT and PET scanners per million of the population among comparable nations, with just 10 CT scanners, 8.6 MRI units and 0.5 PET scanners per million. Even when equipment exists, staff shortages mean it is often not used. One survey respondent arrived for a CT scan to find no staff available to operate the machine.

In August 2025, only 69% of patients began treatment within 62 days of urgent referral—far below the 85% target, which has not been met since December 2015. That is the fault not of this Government but of the last one, but this Government need to make some improvements.

Early diagnosis is key to survival, yet 73% of hospitals are failing to meet the 62-day target. Between January and July 2025, only 66.7% of breast cancer patients began treatment within 62 days of referral. According to data from Breast Cancer Now, if the 85% target had been met each month, 2,931 more people would have started treatment on time. Even under Labour we are continuing to struggle. The Government are not making enough of a difference yet. But I must say again that the problems in the NHS are down to 14 years of Conservative Governments.

Best practice recommends a triple assessment, a clinical exam, imaging and biopsy in a single appointment, yet between 2020 and 2022 only 68% of people received that, due to staff shortages. The failure to streamline diagnosis creates delays and backlogs. Nearly everyone who is diagnosed with bowel cancer early survives for five years, but only one in 10 survive if they are diagnosed late. Still, just 38% of patients in England are diagnosed at stages 1 or 2. One respondent shared how her daughter, who was diagnosed with stage 4 bowel cancer, waited months to start treatment due to delays caused by workforce issues.

In July 2025, only 50% of lower gastrointestinal cancer patients were treated within 62 days of referral, although 93% began treatment within 31 days of a decision to treat. That shows that the delays occur early in the diagnostic process. At the same time, 91,400 people were waiting for a colonoscopy or a sigmoidoscopy. Around 28% waited for more than six weeks and 13% for more than 13 weeks. The Government must increase endoscopy and pathology capacity, and that requires the improvement of staffing levels.

Less survivable cancers—lung, liver, brain, oesophageal, pancreatic and stomach—are most affected by workforce shortages. Only 35% of pancreatic cancer patients receive treatment within 62 days. Less survivable cancers account for 20% of cases but cause 42% of cancer deaths, with a five-year survival rate of just 16%, compared with 55% in more survivable cancers. A new national cancer plan must include a strategy specifically for less-survivable cancers.

Between 2015 and 2023, one in four leukaemia patients faced avoidable diagnostic delays. A Leukaemia UK survey found that insufficient phlebotomy capacity was the top reason for delays in basic full-blood-count tests—a simple, inexpensive diagnostic tool. Acute myeloid leukaemia patients who faced avoidable delays were 22% more likely to die within a year of diagnosis. The Government should audit and invest in phlebotomy services, as called for by Leukaemia UK and the Royal College of General Practitioners. The Government also need to establish a national register of available phlebotomy sites.

Cancer remains a leading cause of death from disease among teenagers and young adults, but it is too often missed. Around 46.3% of 16 to 24-year-olds saw a GP three or more times before diagnosis, according to the Teenage Cancer Trust. That diagnosis delay is exacerbated by a nationwide decline in GPs, meaning longer waits and reduced access to diagnostic services. The national cancer plan and workforce plan must ensure that all frontline healthcare professionals—from GPs to A&E staff and opticians—are trained to recognise cancer symptoms in young people. Services in deprived areas also need support. Those communities face heavier workloads, greater pressure and less funding. The Government must provide targeted support for those areas.

Forty-three per cent of brain tumour patients saw a healthcare professional three or more times before diagnosis, and 55% of parents said their child’s tumour was misdiagnosed. In 2020, 45% of brain tumours were diagnosed in emergency settings—double the 22.5% for all cancers.

According to the Brain Tumour Charity, shortages of neuroradiologists and limited imaging access, alongside GP training gaps, have caused these delays. GPs should be allowed to request neuroimaging directly for concerning symptoms. For prostate cancer, in July 2025, only 55% of men began treatment within 62 days—a 5% drop since January. Even this year, we are still heading in the wrong direction. Men are waiting weeks or months for MRI and biopsy results due to staff shortages. England also has one of the lowest numbers of radiologists per head of population in Europe, a situation that must be rectified.

Clinical nurse specialists are essential to patient support, yet in 2024, 31% of blood cancer patients did not know who their clinical nurse specialist was, and 22% did not know how to contact them. That information is from Blood Cancer UK. Among secondary breast cancer patients in 2019, 25% had not seen a CNS since diagnosis, and only 65% said their CNS had sufficient time for them. For leukaemia, just 9% were offered a holistic needs assessment, which CNSs help to deliver. The national cancer plan must ensure that every patient has access to a CNS, but instability is worsening.

The Royal College of Radiologists’ 2024 census found that colorectal oncology has the highest locum reliance, at 13%. One in five colorectal consultants will retire within the next five years. How are we going to replace those healthcare professionals? The British Association of Urological Surgeons reports that 12% of consultant roles are unfilled, with a growing reliance on costly locums.

In haematology, the east midlands has twice as many vacancies as filled clinical scientist roles, with 32% of haematology clinicians planning to reduce their working hours. Again, the Royal College of Radiologists reports that the median age of radiologists leaving fell from 56 in 2021 to 49 in 2024, and for clinical oncologists from 59 to 54 in one year. Around 20% of clinical oncology consultants will retire in the next five years.

The NHS is losing staff faster than it can replace them. What will the Government do to replace those doctors before they retire? People with less survivable cancers often have rapid disease progression and experience severe symptoms. Around 70% of pancreatic cancer patients receive no active treatment; many are too unwell or diagnosed too late.

Specialist symptom management and supportive care must be expanded to reduce emergency admissions and improve quality of life, yet the NHS cannot currently deliver this. Less survivable cancers must have their own section in the national cancer plan. Advanced treatments such as CAR T-cell therapy for leukaemia are not available everywhere due to a lack of trained staff and infrastructure, resulting in a postcode lottery for lifesaving treatment. The Government must invest in training, especially in primary care, and increase specialist training places in radiology and oncology, as called for by the Royal College of Radiologists. The Government must also end recruitment freezes. On research, only 12% of brain tumour patients have taken part in a clinical trial, and 42% say they were never informed about opportunities to be part of a trial. Investment is needed in research, nurses, radiographers and infrastructure, as well as in embedding research into routine care and protecting staff time to deliver trials.

The Royal College of Radiologists is clear that delays caused by staffing gaps are endangering patients. Without investment, waiting times will lengthen, treatment delays will worsen and costs will rise. I hope it is clear to all of us that workforce shortfalls are a massive barrier to early diagnosis and effective, timely treatment across all cancers. The Government must increase recruitment, training and retention, support primary care referrals, invest in diagnostic infrastructure and education, guarantee access to clinical nurse specialists and prioritise support for patients with less-survivable cancers. Those steps must underpin the national cancer plan and the 10-year workforce plan. Lives depend upon it.

[Several hon. Members rose—]

--- Later in debate ---

[Clive Jones]

I thank you, Mrs Hobhouse, and the Minister for leaving me time to sum up the debate. I thank my hon. Friend the Member for North Shropshire (Helen Morgan) for her contribution and her kind remarks, and I thank other Members for their kind remarks as well. I thank all hon. Members who have contributed so much to today’s debate, each having special stories to tell about the areas they represent. All of them are fantastic campaigners for the cancer community.

We can all agree with the hon. Member for Strangford (Jim Shannon): we all hate cancer. In fact, I am sure everybody in this room today hates cancer.

[Dr Caroline Johnson]

Will the hon. Gentleman give way?

[Clive Jones]

I will make some progress.

I must also say a big thank you to all the cancer charities and life sciences companies that have provided valuable insight into the state of the NHS workforce and its effect on cancer patients. The impact of NHS workforce levels on cancer patients is a serious topic that needs to be discussed, and the experience of patients needs to be highlighted. Today has raised key demands for the Government to address.

The Government must increase endoscopy and pathology capacity. They should audit and invest in phlebotomy services, as called for by Leukaemia UK and the Royal College of General Practitioners. They also need to establish a national register of phlebotomy sites. The Government need to provide targeted support for the most deprived areas of the country, which are under immense pressure, and they need to replace doctors who they know are likely to retire in the next few years.

The Government must up their game on cancer. They have been left a very difficult legacy, with no money and no enthusiasm to change the way we deal with cancer, which is a really sad indictment of the previous Conservative Government. Finally, the Government must increase recruitment, training and retention; support primary care referrals; invest in diagnostic infrastructure and education; guarantee access to clinical nurse specialists; and prioritise support for patients with less survivable cancers.

Question put and agreed to.

Resolved,

That this House has considered the impact of NHS workforce levels on cancer patients.

NHS 10-Year Plan

Clive Jones Excerpts

Thursday 3rd July 2025 Commons Chamber

[Wes Streeting]

I thank my hon. Friend for his service to our country and our NHS. We are so lucky to have his expertise in the House. I am really proud that this Government will deliver mental health support in every primary and secondary school in the country and neighbourhood mental health services in every community. We will also ensure that people who are in mental health crisis do not end up in busy, noisy, overwhelming A&E departments, but will instead go to new mental health emergency departments, which we aim to roll out across 50% of type 1 A&E departments—either co-located or, if not, certainly nearby. I look forward to working with him on that.

My hon. Friend is quite right to emphasise the importance of talking therapies. That is how we not only help people to achieve their best when they are young and in education, but ensure that people are supported to stay in the world of work or to find work. We know there is a demonstrable link between mental health and wellbeing, good work and good outcomes. That is very relevant this week.

[Clive Jones (Wokingham) (LD)]

I welcome the Secretary of State’s 10-year plan. In October, in response to my Westminster Hall debate on the national cancer plan, the Government committed to publishing one later this year. I am confident that that will happen in the autumn, and the wider cancer community is equally enthusiastic. However, the 10-year plan announced today makes only a brief mention of the national cancer plan. Can the Secretary of State confirm that improved diagnosis, improved screening for at-risk groups, improved treatment outcomes, concentration on rare cancers and cancers in young people, better and continued workforce planning, more support and funding for research, better relationships with drug companies and much more will be part of the national cancer plan?

[Wes Streeting]

I thought for a moment there that the hon. Gentleman, having called for the plan, was going to write it. I can reassure him that he has covered all the right areas; I am delighted that he is as enthusiastic as we and the whole cancer community are about the plan. We deliberately did not go into specific conditions in the 10-year plan for health, because otherwise it would have turned into a Christmas tree, with every condition group trying to attach its bauble to it, but it is really important that this 10-year plan creates the rising tide that lifts all ships—including, as he notes, not just common conditions, but the rare ones too.

Rare Cancers Bill

Clive Jones Excerpts

Committee stage
Wednesday 2nd July 2025 Public Bill Committees

[Ashley Dalton]

I should clarify that there is no regional specificity in the allocation of research funding. We welcome all funding bids for research on cancer and rare cancers from anywhere in the country, and I encourage them to come forward.

The new power in clause 3 to allow patient data from NHS England information systems to be shared will allow more patients to be contacted about existing trials. Practically, it will allow us to join up data from the national disease registration service with “Be Part of Research”. As I have said, we are encouraging people to bring forward more research proposals, all of which are considered.

For the first time, patients with a rare cancer could be automatically contacted about research opportunities that are relevant to them and offered innovative new treatments, which means rare cancer patients could have access to research at their fingertips. That is the kind of change that the Government support as part of the shift we are making from analogue to digital—one of the three shifts that will be covered in the 10-year plan that will be launched tomorrow, when more details will become clear.

Clause 4 covers the Bill’s territorial extent. Due to practical and legal differences between the nations, the devolved Governments did not wish to legislate in their individual countries. Our manifesto promised to reset our relationship with the devolved Governments, and we have developed the Bill with them. I am delighted that they expressed their support on Second Reading. Clauses 5 and 6 cover the Bill’s commencement and title. The Government are fully committed to supporting the Bill through the next stages so it can become the Rare Cancers Act 2025.

The shadow Minister talked about the national cancer plan, which I can confirm is being worked on. We have had over 11,000 representations on that plan, which will be published later this year, following the publication of the national 10-year plan for health tomorrow. The children and young people cancer taskforce was launched earlier this year and continues to meet, and has now ensured that young people and children’s voices are part of the taskforce.

[Clive Jones (Wokingham) (LD)]

When the national cancer strategy is published, I hope that part of it will focus on boosting the survival rates for rare cancers. Will the Minister confirm that that will be an important part of the strategy?

[Ashley Dalton]

I can confirm that the overall objective of the whole cancer plan will be saving lives and reducing the number of lives lost to cancer, including rare cancers. The plan will be published later this year.

It is important to note that the Bill is specific to cancer; there will be opportunities to discuss other rare conditions in the future. I thank my hon. Friend the Member for Edinburgh South West for presenting the Bill, and I pay tribute to the charities that are backing him, some of which I had the pleasure to meet recently to discuss further how the Government can better support people with rare cancers. Together, we will improve outcomes for people across our country, and I look forward to working with everybody to get that done.

Prostate Cancer Treatment

Clive Jones Excerpts

Tuesday 17th June 2025 Commons Chamber

[Dr Rupa Huq (Ealing Central and Acton) (Lab)]

Joe Biden’s recent diagnosis has to some extent put prostate cancer in the spotlight of late, but it is not just him—there is Stephen Fry, Jools Holland and Robert De Niro. More than 50,000 men in the UK and 1.4 million men worldwide are diagnosed with prostate cancer yearly, which is projected to double by 2040. With one in eight men diagnosed during their life, it is the most common male cancer. More than half of those men are pre-retirement age, such as the cyclist Sir Chris Hoy, who was diagnosed at 48, but 70-plus is the most common age.

My late dad was 69 when he was diagnosed. He left this earth just shy of his 79th birthday in August 2014, so he had 10 years. It is often said that men die with prostate cancer, not of it. With my dad, it spread to bone cancer, but pneumonia was actually the cause of death on the certificate. I miss him every day.

Treatment for prostate cancer has improved dramatically since then. One crucial breakthrough is the development of the drug abiraterone, a Great British success story discovered and initially developed in London at the Institute of Cancer Research. It is a shining example of British science leading the world and revolutionising advanced prostate cancer care.

[Clive Jones (Wokingham) (LD)]

Will the hon. Member reiterate a question that I have for the Minister? Specifically, given that abiraterone is already approved for use in Scotland and Wales, what action is the Minister taking to ensure that men in England are not disadvantaged in accessing lifesaving cancer treatments?

[Dr Huq]

The hon. Member reads my mind about the postcode lottery, which I will come to in my list of questions. I know that my hon. Friend the Minister is very sympathetic and on the right side.

Abiraterone is now a global drug. Half a million men around the world have had transformed outcomes, improved quality of life and extra years spent with loved ones.

Oral Answers to Questions

Clive Jones Excerpts

Tuesday 17th June 2025 Commons Chamber

[Wes Streeting]

My hon. Friend is absolutely right. Just as this Government are delivering record home building with a huge target to build the homes that Britain needs, we also need to ensure that people get the local services that they deserve. That is exactly why this Government have invested an extra £102 million this year to create additional clinical space in over 1,000 GP practices, which will create new consultation rooms and make better use of existing space to deliver more appointments. I know the Chineham medical practice was one of the practices put forward by its integrated care board for funding, so I hope we will see that practice benefiting from this investment in the near future as we rebuild our NHS.

[Clive Jones (Wokingham) (LD)]

The Government’s additional roles reimbursement scheme led to just three new GPs for my constituents in Wokingham, which is a drop in the ocean. More needs to be done to deliver GP practices in new developments such as Arborfield in south Wokingham. Why did Ministers not support the Liberal Democrat amendment to the Planning and Infrastructure Bill that would have made commitments to build GP surgeries in all new housing developments legally binding?

Spending Review: Health and Social Care

Clive Jones Excerpts

Thursday 12th June 2025 Commons Chamber

[Karin Smyth]

My hon. Friend has been such a strong and powerful campaigner for women’s health since becoming an MP last year, and she is absolutely right to do that. I am pleased that we have been able to make some progress on conditions such as endometriosis. Many campaigns have been fought by many women in this House—including you, Madam Deputy Speaker, if I may say so—to highlight the importance of this issue. We see women’s health as front and centre. We want to learn from the women’s health hubs in their different guises and ensure that they are an integral part of neighbourhood health services.

[Clive Jones (Wokingham) (LD)]

I was really saddened that there was no mention of cancer in the Minister’s statement, so I will give her the opportunity to correct that omission. Will this new money for our NHS ensure that all cancer waiting time targets are met by the end of this Parliament, and can the Minister confirm that those targets will be included in the 10-year health plan? Finally, have Ministers had a chance to read my 11-page letter and accompanying submission on what should be in the national cancer plan?

[Karin Smyth]

I have a slight “get out of jail free” card, because I think that letter might be with one of my colleagues, not with me. Obviously, though, I look forward to the summary.

The hon. Gentleman makes a really important point about cancer. I would have to check, but I do not think I mentioned lots of disease-specific areas, including key manifesto commitments such as dentistry. Obviously, cancer is a huge part of waiting lists overall. We will get those waiting lists down—we are determined to meet that target—and we will issue a cancer plan later in the year.

GP Services: Christchurch

Clive Jones Excerpts

Tuesday 20th May 2025 Westminster Hall

[Sir Christopher Chope]

The hon. Gentleman mentions the issue of finances. I tabled a written question about how much the health service has been spending on general practice in the Christchurch constituency. Again, rather surprisingly, the information is available only for the year ending 2023, so we do not have any information for 2023–24. Although I would not expect the figures for 2024–25 to be available, I certainly would have expected the total costs for 2023–24 to be available by now. The answer says that in 2022–23, some £17.5 million was spent on providing GP services in Christchurch.

The idea that the cost of transferring patients from one practice to another should be a decisive factor against the reopening of a branch seems extraordinary. It makes a nonsense of the argument that we must rein in our expenditure. While we are talking about the ICB’s expenditure, for the last several years I have been complaining that, at any given time in Dorset, under the ICB’s supervision, there are some 250 patients in Dorset hospitals who have no need to “reside”, as it is called. In other words, those people are in hospital but do not need to be there. Every day, that is 250 patients at a cost of between £500 and £1,000 each.

The same body is presiding over that scandal. It said last year that it was going to halve the number, but it has failed to do so—indeed, the number is just the same as a year ago. Instead of taking it out on the people of Christchurch and saying, “You can’t have access to a reopened branch surgery,” it should be looking at its own poor performance. As I have said to the Minister informally, the idea that Dorset ICB will somehow be amalgamated with other ICBs—creating even more bureaucracy, and making it even more remote from the people—is, again, farcical.

My final point—I want to give the Minister time to respond—is that, in answer to a written question, the Minister for Care said that as a result of what has happened in the last year, the number of patients in Highcliffe has increased by about 150. In Christchurch medical practice, the total number of patients has actually fallen; in the Stour surgery, it has increased; and in the Grove, it is about the same. To suggest, on those figures, that the financial viability of other practices in Christchurch will be threatened if this branch surgery is reopened seems to be without any justification. I hope that the Minister will be able to give a positive response, although I note that the Minister for Care is not responding to the debate.

[Clive Jones (Wokingham) (LD)]

Will the hon. Gentleman give way?

[Sir Christopher Chope]

I will not, because I want to ensure that the Minister has time to respond to those points.

[The Minister for Secondary Care (Karin Smyth)]

It is a pleasure to serve under your chairmanship this morning, Mr Dowd. I thank the hon. Member for Christchurch (Sir Christopher Chope) for raising GP surgeries, which is a vital matter to so many of our constituents. That is because GP surgeries are the front door to our NHS, and visiting a GP represents far better value for taxpayers’ money than accident and emergency departments. That is why, since coming into office, fixing general practice has rightly taken up a lot of our bandwidth, energy and focus.

It is worth remembering that we inherited a system in total disarray, and a bizarre situation in which we simultaneously had a GP shortage and newly qualified GPs looking for work. I am proud of everything we have done to turn GP services around in the nine or 10 short months we have had. However, before I come on to that, let me address some of the hon. Gentleman’s points.

Ahead of this debate, I asked my office to get in touch with the integrated care board locally so that we had a fuller picture of what is happening on the ground. My understanding is that Burton surgery was previously a branch of Christchurch medical practice, which is just under two miles away. The surgery closed in August last year because the owners wanted to sell. Although the ICB did not approve of the closure, it recognised that it had little influence over the sale as GPs are independent practitioners.

I am informed that the local community were—as they often are—understandably unhappy with the news about changes to the services, and that the hon. Gentleman got in touch with Dorset ICB. When a veterinary business tried to buy the site, the application received over 100 objection letters and the sale did not go ahead. The ICB then received two further applications to renew the site, about which it considered a number of factors, as is normal practice: whether there is good access to surgeries in the area; what the impact would be on patients and on community needs; how it would affect the quality, equity and safety of provision; and how it might affect the stability and ability of other local GP services to run viable surgeries in their area.

I have been assured that the decision that Dorset ICB took was not taken lightly but based on the needs of and the benefits to all prospective patients in the area. The surgery catchment area for Burton is covered by Christchurch medical practice and Farmhouse surgery. As the hon. Gentleman outlined, reopening would have required additional costs, which were not justifiable given the financial challenges facing the NHS—something that we all understand. Consequently, Dorset ICB felt that those costs would reduce provision in the area and lead to significant financial pressures on other local surgeries, which could lead to further closures.

Dorset ICB has seen no degradation of services for patients since the surgery closed and the number of appointments has not decreased overall. I take the hon. Gentleman’s point about the numbers, and I do not know why that information is not available; I am happy to take that question back to the Department. Local MPs should have as much information as possible about services in their areas. These are taxpayer-funded services, so I will check as to why that information is not available. Dorset ICB has not received what it calls formal complaints from patients, but it has received communications from a local campaigning group, which is important. On balance, however, it decided that it could not reopen the practice.

On the point about housing needs, which I talked about for many years when I was an Opposition Member of Parliament, the Government absolutely understand the issue of additional demand and the challenge it poses to primary care infrastructure.

[Clive Jones]

Will the Minister give way?

[Karin Smyth]

I will not, because the hon. Member for Christchurch wants me to answer his questions.

We are working closely with the Secretary of State for Housing, Communities and Local Government to address the issue of additional demand in national planning guidance and ensure that all new and existing developments have an adequate level of healthcare infrastructure for the community. The NHS has a statutory duty to ensure that there are sufficient medical services, including general practice, in each local area, with funding and commission reflecting population growth and demographic changes. The hon. Gentleman highlights an important point that we will continue to pursue.

Those are the facts about the decision made by the ICB, which was its decision to make. I am not going to stand here and tell the hon. Gentleman that he is not right to do what he is doing; he is absolutely right to fight for the best possible service provision for the people of Christchurch, and I would do the same for my constituents—all hon. Members do that. These decisions are best made locally, however, and it is for Dorset ICB to use its autonomy to make them, not Ministers in Whitehall.